Highlights: * New details on ATH34 Phase 2 clinical trial released. * Data from bioMUSE present...
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding ...
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ...
MEMPHIS, Tenn., Aug. 29, 2021 /PRNewswire/ -- Innovative US based biotech companyTriad Life Science...
MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial...
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...